Lysosomal drug sequestration as a mechanism of drug resistance in vascular sarcoma cells marked by high CSF-1R expression

Vascular Cell

Volumn 6, Issue 1, 2014, Pages

  Gorden, Brandi H ^a   Saha, Jhuma ^a   Khammanivong, Ali ^a   Schwartz, Gary K ^b   Dickerson, Erin B ^a,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Department of Medicine   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Angiosarcoma; Chemoresistance; CSF 1R; Endothelial; Hemangiosarcoma; Lysosome; Myeloid

Indexed keywords

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; COLONY STIMULATING FACTOR 1 RECEPTOR; CYTOKINE RECEPTOR; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN 1; UNCLASSIFIED DRUG;

ANGIOSARCOMA; ANIMAL CELL; ARTICLE; BONE MARROW CELL; CANCER CELL LINE; CELL POPULATION; CELL VIABILITY ASSAY; CELLULAR DISTRIBUTION; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG RESISTANCE; EC50; ENDOTHELIAL PROGENITOR CELL; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LYSOSOME; NONHUMAN; PHAGOCYTOSIS; PROTEIN EXPRESSION; SARCOMA CELL; VASCULAR SARCOMA CELL;

EID: 84907813255     PISSN: 2045824X     EISSN: 2045824X     Source Type: Journal    
DOI: 10.1186/2045-824X-6-20     Document Type: Article

References (45)

1. Andersen NJ, Froman RE, Kitchell BE, Duesbery NS: Clinical and Molecular Biology of Angiosarcoma. In Soft Tissue Tumors. Edited by Derbel F. Rijeka, Croatia: InTech; 2011:149-174.
2. Clifford CA, Mackin AJ, Henry CJ: Treatment of canine hemangiosarcoma: 2000 and beyond. J Vet Intern Med 2000, 14(5):479-485.
3. Cioffi A, Reichert S, Antonescu CR, Maki RG: Angiosarcomas and other sarcomas of endothelial origin. Hematol Oncol Clin North Am 2013, 27(5):975-988.
4. Vail DM, MacEwen EG: Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest 2000, 18(8):781-792.
5. Cohen SM, Storer RD, Criswell KA, Doerrer NG, Dellarco VL, Pegg DG, Wojcinski ZW, Malarkey DE, Jacobs AC, Klaunig JE, Swenberg JA, Cook JC: Hemangiosarcoma in rodents: mode-of-action evaluation and human relevance. Toxicol Sci 2009, 111(1):4-18.
6. Lamerato-Kozicki AR, Helm KM, Jubala CM, Cutter GC, Modiano JF: Canine hemangiosarcoma originates from hematopoietic precursors with potential for endothelial differentiation. Exp Hematol 2006, 34(7):870-878.
7. Tamburini BA, Phang TL, Fosmire SP, Scott MC, Trapp SC, Duckett MM, Robinson SR, Slansky JE, Sharkey LC, Cutter GR, Wojcieszyn JW, Bellgrau D, Gemmill RM, Hunter LE, Modiano JF: Gene expression profiling identifies inflammation and angiogenesis as distinguishing features of canine hemangiosarcoma. BMC Cancer 2010, 10:619.
8. Gorden BH, Kim JH, Sarver AL, Frantz AM, Breen M, Lindblad-Toh K, O'Brien TD, Sharkey LC, Modiano JF, Dickerson EB: Identification of three molecular and functional subtypes in canine hemangiosarcoma through gene expression profiling and progenitor cell characterization. Am J Pathol 2014, 184(4):985-995.
9. Liu L, Kakiuchi-Kiyota S, Arnold LL, Johansson SL, Wert D, Cohen SM: Pathogenesis of human hemangiosarcomas and hemangiomas. Hum Pathol 2013, 44(10):2302-2311.
10. Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F, Krasich R, Temm CJ, Prchal JT, Ingram DA: Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007, 109(5):1801-1809.
11. Chitu V, Stanley ER: Colony-stimulating factor-1 in immunity and inflammation. Curr Opin Immunol 2006, 18(1):39-48.
12. Lin H, Lee E, Hestir K, Leo C, Huang M, Bosch E, Halenbeck R, Wu G, Zhou A, Behrens D, Hollenbaugh D, Linnemann T, Qin M, Wong J, Chu K, Doberstein SK, Williams LT: Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science 2008, 320(5877):807-811.
13. Liu H, Leo C, Chen X, Wong BR, Williams LT, Lin H, He X: The mechanism of shared but distinct CSF-1R signaling by the non-homologous cytokines IL-34 and CSF-1. Biochim Biophys Acta 2012, 1824(7):938-945.
14. Nandi S, Gokhan S, Dai XM, Wei S, Enikolopov G, Lin H, Mehler MF, Stanley ER: The CSF-1 receptor ligands IL-34 and CSF-1 exhibit distinct developmental brain expression patterns and regulate neural progenitor cell maintenance and maturation. Dev Biol 2012, 367 (2):100-113.
15. Wei S, Nandi S, Chitu V, Yeung YG, Yu W, Huang M, Williams LT, Lin H, Stanley ER: Functional overlap but differential expression of CSF-1 and IL-34 in their CSF-1 receptor-mediated regulation of myeloid cells. J Leukoc Biol 2010, 88(3):495-505.
16. Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, Belaygorod L, Carpenter D, Collins L, Piwnica-Worms D, Hewitt S, Udupi GM, Gallagher WM, Wegner C, West BL, Wang-Gillam A, Goedegebuure P, Linehan DC, DeNardo DG: Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res 2013, 73(3):1128-1141.
17. Priceman SJ, Sung JL, Shaposhnik Z, Burton JB, Torres-Collado AX, Moughon DL, Johnson M, Lusis AJ, Cohen DA, Iruela-Arispe ML, Wu L: Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood 2010, 115(7):1461-1471.
18. Aharinejad S, Abraham D, Paulus P, Abri H, Hofmann M, Grossschmidt K, Schafer R, Stanley ER, Hofbauer R: Colony-stimulating factor-1 antisense treatment suppresses growth of human tumor xenografts in mice. Cancer Res 2002, 62(18):5317-5324.
19. Aharinejad S, Paulus P, Sioud M, Hofmann M, Zins K, Schafer R, Stanley ER, Abraham D: Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res 2004, 64(15):5378-5384.
20. Paulus P, Stanley ER, Schafer R, Abraham D, Aharinejad S: Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts. Cancer Res 2006, 66(8):4349-4356.
21. Cioce M, Canino C, Goparaju C, Yang H, Carbone M, Pass HI: Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation. Cell Death Dis 2014, 5:e1167.
22. Fosmire SP, Dickerson EB, Scott AM, Bianco SR, Pettengill MJ, Meylemans H, Padilla M, Frazer-Abel AA, Akhtar N, Getzy DM, Wojcieszyn J, Breen M, Hefland SC, Modiano JF: Canine malignant hemangiosarcoma as a model of primitive angiogenic endothelium. Lab Invest 2004, 84(5):562-572.
23. Akhtar N, Padilla ML, Dickerson EB, Steinberg H, Breen M, Auerbach R, Helfand SC: Interleukin-12 inhibits tumor growth in a novel angiogenesis canine hemangiosarcoma xenograft model. Neoplasia 2004, 6(2):106-116.
24. Italiano A, Chen CL, Thomas R, Breen M, Bonnet F, Sevenet N, Longy M, Maki RG, Coindre JM, Antonescu CR: Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: a pattern distinct from other sarcomas with complex genomics. Cancer 2012, 118 (23):5878-5887.
25. Tamburini BA, Trapp S, Phang TL, Schappa JT, Hunter LE, Modiano JF: Gene expression profiles of sporadic canine hemangiosarcoma are uniquely associated with breed. PLoS One 2009, 4(5):e5549.
26. Kim DW, Kim KO, Shin MJ, Ha JH, Seo SW, Yang J, Lee FY: siRNA-based targeting of antiapoptotic genes can reverse chemoresistance in P-glycoprotein expressing chondrosarcoma cells. Mol Cancer 2009, 8:28.
27. Wyman JJ, Hornstein AM, Meitner PA, Mak S, Verdier P, Block JA, Pan J, Terek RM: Multidrug resistance-1 and p-glycoprotein in human chondrosarcoma cell lines: expression correlates with decreased intracellular doxorubicin and in vitro chemoresistance. J Orthop Res 1999, 17(6):935-940.
28. Dini L, Lentini A, Diez GD, Rocha M, Falasca L, Serafino L, Vidal-Vanaclocha F: Phagocytosis of apoptotic bodies by liver endothelial cells. J Cell Sci 1995, 108(Pt 3):967-973.
29. Dean M, Fojo T, Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer 2005, 5(4):275-284.
30. Sharom FJ: ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008, 9(1):105-127.
31. Mathew G, Timm EA Jr, Sotomayor P, Godoy A, Montecinos VP, Smith GJ, Huss WJ: ABCG2-mediated DyeCycle Violet efflux defined side population in benign and malignant prostate. Cell Cycle 2009, 8(7):1053-1061.
32. She JJ, Zhang PG, Wang ZM, Gan WM, Che XM: Identification of side population cells from bladder cancer cells by DyeCycle violet staining. Cancer Biol Ther 2008, 7(10):1663-1668.
33. Hindenburg AA, Gervasoni JE Jr, Krishna S, Stewart VJ, Rosado M, Lutzky J, Bhalla K, Baker MA, Taub RN: Intracellular distribution and pharmacokinetics of daunorubicin in anthracycline-sensitive and -resistant HL-60 cells. Cancer Res 1989, 49(16):4607-4614.
34. Hurwitz SJ, Terashima M, Mizunuma N, Slapak CA: Vesicular anthracycline accumulation in doxorubicin-selected U-937 cells: participation of lysosomes. Blood 1997, 89(10):3745-3754.
35. Honoki K: Do stem-like cells play a role in drug resistance of sarcomas? Expert Rev Anticancer Ther 2010, 10(2):261-270.
36. O'Brien CA, Kreso A, Dick JE: Cancer stem cells in solid tumors: an overview. Semin Radiat Oncol 2009, 19(2):71-77.
37. Antonescu CR, Yoshida A, Guo T, Chang NE, Zhang L, Agaram NP, Qin LX, Brennan MF, Singer S, Maki RG: KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res 2009, 69(18):7175-7179.
38. Gong Y, Duvvuri M, Krise JP: Separate roles for the Golgi apparatus and lysosomes in the sequestration of drugs in the multidrug-resistant human leukemic cell line HL-60. J Biol Chem 2003, 278(50):50234-50239.
39. Lee CM, Tannock IF: Inhibition of endosomal sequestration of basic anticancer drugs: influence on cytotoxicity and tissue penetration. Br J Cancer 2006, 94(6):863-869.
40. Sukhai MA, Prabha S, Hurren R, Rutledge AC, Lee AY, Sriskanthadevan S, Sun H, Wang X, Skrtic M, Seneviratne A, Cusimano M, Jhas B, Gronda M, MacLean N, Cho EE, Spagnuolo PA, Sharmeen S, Gebbia M, Urbanus M, Eppert K, Dissanayake D, Jonet A, Dassonville-Klimpt A, Li X, Datti A, Ohashi PS, Wrana J, Rogers I, Sonnet P, Ellis WY: Lysosomal disruption preferentially targets acute myeloid leukemia cells and progenitors. J Clin Invest 2013, 123(1):315-328.
41. Samudio I, Harmancey R, Fiegl M, Kantarjian H, Konopleva M, Korchin B, Kaluarachchi K, Bornmann W, Duvvuri S, Taegtmeyer H, Andreeff M: Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest 2009, 120(1):142-156.
42. Glaumann H, Motakefi AM, Jansson H: Intracellular distribution and effect of the antimalarial drug mefloquine on lysosomes of rat liver. Liver 1992, 12(4 Pt 1):183-190.
43. Chapuy B, Koch R, Radunski U, Corsham S, Cheong N, Inagaki N, Ban N, Wenzel D, Reinhardt D, Zapf A, Schweyer S, Kosari F, Klapper W, Truemper L, Wulf GG: Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration. Leukemia 2008, 22(8):1576-1586.
44. Chapuy B, Panse M, Radunski U, Koch R, Wenzel D, Inagaki N, Haase D, Truemper L, Wulf GG: ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug. Haematologica 2009, 94(11):1528-1536.
45. Yamagishi T, Sahni S, Sharp DM, Arvind A, Jansson PJ, Richardson DR: P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration. J Biol Chem 2013, 288(44):31761-31771.